MASSACHUSETTS BIOLOGIC LABORATORIES, MEDAREX ANNOUNCE PRIMARY OBJECTIVE ACHIEVED IN PHASE TWO TRIAL
November 03, 2008
November 03, 2008
JAMAICA PLAIN, Mass., Nov. 3 -- The University of Massachusetts Medical School issued the following press release:
Medarex, Inc. (Nasdaq: MEDX) and The Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) today announced that a Phase 2 trial of an anti-C. difficile antibody combination treatment in patients with C. difficile Associated Diarrhea (CDAD) successfully met its primary objective. The top-line results from the recently comple . . .
Medarex, Inc. (Nasdaq: MEDX) and The Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) today announced that a Phase 2 trial of an anti-C. difficile antibody combination treatment in patients with C. difficile Associated Diarrhea (CDAD) successfully met its primary objective. The top-line results from the recently comple . . .